

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 19, 2021
PDL Changes Effective Date: January 1, 2022



***The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2022, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

| NEW PREFERRED DRUGS | |
|---|--|
| THERAPEUTIC CLASS | RECOMMENDED for PREFERRED STATUS |
| ANTICONVULSANTS, ADJUVANTS | EPIDIOLEX (cannabidiol) |
| ANTIFUNGALS (VAGINAL) | miconazole 3 vaginal cream, suppository ^{OTC} |
| ANTIFUNGALS (VAGINAL) | terconazole cream |
| ANTIMIGRAINE AGENTS, ACUTE TREATMENT, NASAL | zolmitriptan spray |
| ANTIRETROVIRALS, SINGLE PRODUCT REGIMENS | CABENUVA (cabotegravir/rilpivirine) |
| ANTIRETROVIRALS, SINGLE PRODUCT REGIMENS | DOVATO (dolutegravir/lamivudine) |
| ANTIRETROVIRALS, SINGLE PRODUCT REGIMENS | JULUCA (dolutegravir/rilpivirine) |
| ANTIRETROVIRALS, SINGLE PRODUCT REGIMENS | TRIUMEQ (abacavir/lamivudine/ dolutegravir) |
| ATOPIC DERMATITIS | DUPIXENT (dupilumab) |
| ATOPIC DERMATITIS | ELIDEL (pimecrolimus) |
| ATOPIC DERMATITIS | PROTOPIC (tacrolimus) |
| BRONCHODILATORS & COPD AGENTS | INCRUSE ELLIPTA (umeclidinium) |
| BRONCHODILATORS & COPD AGENTS | STIOLTO RESPIMAT (tiotropium/olodaterol) |
| BRONCHODILATORS, BETA AGONIST | STRIVERDI RESPIMAT (olodaterol) |
| COLONY STIMULATING FACTORS | ZIEXTENZO (pegfilgrastim-bmez) |
| CYTOKINE & CAM ANTAGONISTS | ACTEMRA (tocilizumab) SYRINGE |
| CYTOKINE & CAM ANTAGONISTS | ACTEMRA VIAL (tocilizumab) |
| CYTOKINE & CAM ANTAGONISTS | AVSOLA (infliximab) |
| CYTOKINE & CAM ANTAGONISTS | KINERET (anakinra) |
| CYTOKINE & CAM ANTAGONISTS | ORENCIA CLICKJET (abatacept) |

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 19, 2021
PDL Changes Effective Date: January 1, 2022



| NEW PREFERRED DRUGS | |
|--|---|
| THERAPEUTIC CLASS | RECOMMENDED for PREFERRED STATUS |
| CYTOKINE & CAM ANTAGONISTS | ORENCIA VIAL (abatacept) |
| CYTOKINE & CAM ANTAGONISTS | OTEZLA (apremilast) |
| CYTOKINE & CAM ANTAGONISTS | SIMPONI (golimumab) |
| FACTOR DEFICIENCY PRODUCTS, FACTOR VIII | KOVALTRY |
| FACTOR DEFICIENCY PRODUCTS, FACTOR IX | IDELVION |
| FACTOR DEFICIENCY PRODUCTS, OTHER FACTOR PRODUCTS | HEMLIBRA |
| HYPERURICEMIA & GOUT | colchicine tablet |
| HYPOGLYCEMICS, INSULINS AND RELATED AGENTS | HUMULIN R U500 KWIKPEN |
| HYPOGLYCEMICS, INSULINS AND RELATED AGENTS | insulin lispro junior kwikpen |
| IMMUNE GLOBULINS | BIVIGAM |
| IMMUNE GLOBULINS | GAMMAGARD SD |
| IMMUNE GLOBULINS | PRIVIGEN |
| IMMUNOLOGIC THERAPIES FOR ASTHMA | DUPIXENT (dupilumab) |
| LIPOTROPICS, OTHER (NON-STATINS), PCSK-9 INHIBITOR | PRALUENT (alirocumab) |
| LIPOTROPICS, OTHER (NON-STATINS), PCSK-9 INHIBITOR | REPATHA (evolocumab) |
| MULTIPLE SCLEROSIS AGENTS | dimethyl fumarate |
| OPHTHALMIC, GLAUCOMA AGENTS, COMBINATION AGENTS | SIMBRINZA (brinzolamide/brimonidine) |
| OPHTHALMIC, GLAUCOMA AGENTS, SYMPATHOMIMETICS | ALPHAGAN P 0.1% (brimonidine) |
| OPHTHALMIC, GLAUCOMA AGENTS, SYMPATHOMIMETICS | ALPHAGAN P 0.15% (brimonidine) |
| OPIATE DEPENDENCE TREATMENTS, TREATMENTS | KLOXXADO (naloxone) |
| OTIC ANTIBIOTICS | CORTISPORIN-TC (colistin/neomycin/ |

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 19, 2021
PDL Changes Effective Date: January 1, 2022



| NEW PREFERRED DRUGS | |
|--|---|
| THERAPEUTIC CLASS | RECOMMENDED for PREFERRED STATUS |
| | hydrocortisone) |
| OTIC ANTIBIOTICS | neomycin/polymyxin/hydrocortisone |
| PLATELET STIMULATING AGENTS | NPLATE (romiplostim) |
| PRENATAL VITAMINS | COMPLETENATE CHEW TAB |
| PRENATAL VITAMINS | NESTABS DHA COMBO PKG |
| PRENATAL VITAMINS | PNV 29-1 TAB |
| PRENATAL VITAMINS | PNV 95/Fe/FA TAB (labeler 00536) |
| PRENATAL VITAMINS | PNV 137/Fe/FA TAB (labeler 00904) |
| PRENATAL VITAMINS | PNV-DHA SOFTGEL CAP |
| PRENATAL VITAMINS | SE-NATAL19 CHEW TAB |
| PRENATAL VITAMINS | SE-NATAL19 TAB |
| PRENATAL VITAMINS | THRIVITE RX TAB |
| PRENATAL VITAMINS | VIRT-NATE DHA SOFTGEL CAP |
| PRENATAL VITAMINS | VP-PNV-DHA SOFTGEL CAP |
| PRENATAL VITAMINS | WESTAB PLUS TAB |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | AUROVELA 24 FE (norethindrone/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | BLISOVI 24 FE (norethindrone/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | BRIELLYN (norethindrone/ethinyl estradiol) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | drospirenone/ethinyl estradiol tab |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | HAILEY 24 FE (norethindrone/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | JUNEL 24 FE (norethindrone/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | LARIN 24 FE (norethindrone/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | LAYOLIS FE (norethindrone/ethinyl estradiol/iron) |

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 19, 2021
PDL Changes Effective Date: January 1, 2022



| NEW PREFERRED DRUGS | |
|--|---|
| THERAPEUTIC CLASS | RECOMMENDED for PREFERRED STATUS |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | LORYNA (ethinyl estradiol/drospirenone) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | LO-ZUMANDIMINE (ethinyl estradiol/drospirenone) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | norethindrone/ethinyl estradiol/fe chew tab |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | PHILITH (norethindrone/ethinyl estradiol) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | SYEDA (ethinyl estradiol/drospirenone) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | TARINA 24 FE (norethindrone/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | WYMZYA FE (norethindrone/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | ZARAH (ethinyl estradiol/drospirenone) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | ZUMANDIMINE (ethinyl estradiol/drospirenone) |
| STIMULANTS AND RELATED AGENTS, LONG-ACTING | dextroamphetamine ER |
| STIMULANTS AND RELATED AGENTS, LONG-ACTING | QUILLIVANT XR (methylphenidate) |
| STIMULANTS AND RELATED AGENTS, NON-STIMULANTS | clonidine ER |

| NEW NON-PREFERRED DRUGS | |
|-------------------------------------|---|
| THERAPEUTIC CLASS | RECOMMENDED for NON-PREFERRED STATUS |
| ANTIFUNGALS, ORAL | BREXAFEMME (ibrexafungerp) |
| ANTIMIGRAINE, PROPHYLAXIS | NURTEC ODT (rimegepant) |
| ANTINEOPLASTICS – SELECTED SYSTEMIC | TRUSELTIQ (infigratinib) |

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 19, 2021
PDL Changes Effective Date: January 1, 2022



| NEW NON-PREFERRED DRUGS | |
|---|--|
| THERAPEUTIC CLASS | RECOMMENDED for NON-PREFERRED STATUS |
| ENZYME INHIBITORS | |
| ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS | LUMAKRAS (sotorasib) |
| ATOPIC DERMATITIS | pimecrolimus labeler 68682 |
| BLADDER RELAXANT PREPARATIONS | MYRBETRIQ granules (mirabegron) |
| BLADDER RELAXANT PREPARATIONS | VESICARE LS Suspension (solifenacin) |
| BRONCHODILATORS & COPD AGENTS | BEVESPI (glycopyrrolate/formoterol) |
| BRONCHODILATORS, BETA AGONIST | PROAIR RESPICLICK (albuterol) |
| COLONY STIMULATING FACTORS | GRANIX (tbo-filgrastim) |
| CYSTIC FIBROSIS AGENTS | BETHKIS (tobramycin) |
| CYSTIC FIBROSIS AGENTS | KITABIS (tobramycin) |
| HYPERURICEMIA & GOUT | colchicine capsule |
| HYPOGLYCEMIA TREATMENT, GLUCAGON | glucagon kit (labelers 63323, 00548) |
| IDIOPATHIC PULMONARY FIBROSIS | ESBRIET (pirfenidone) |
| IMMUNE GLOBULINS | OCTAGAM |
| IMMUNOLOGIC THERAPIES FOR ASTHMA | FASENRA PEN AUTOINJECTOR (benralizumab) |
| IMMUNOLOGIC THERAPIES FOR ASTHMA | NUCALA AUTOINJECTOR (mepolizumab) |
| IMMUNOLOGIC THERAPIES FOR ASTHMA | NUCALA SYRINGE (mepolizumab) |
| OPIATE DEPENDENCE TREATEMENTS, DEPENDENCE | buprenorphine/naloxone film labeler 52427 |
| PLATELET STIMULATING AGENTS | PROMACTA POWDER PACK (eltrombopag olamine) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | BALCOLTRA (levonorgestrel/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | LOESTRIN (norethindrone acetate/ethinyl estradiol) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | LOESTRIN FE (norethindrone/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL | MINASTRIN 24 FE (norethindrone/ethinyl |

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 19, 2021
PDL Changes Effective Date: January 1, 2022



| NEW NON-PREFERRED DRUGS | |
|--|--|
| THERAPEUTIC CLASS | RECOMMENDED for NON-PREFERRED STATUS |
| CONTRACEPTIVES | estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | TAYTULLA (norethindrone/ethinyl estradiol/iron) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | TYDEMY (ethinyl estradiol/drospirenone/levomefolate calcium) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | YASMIN (ethinyl estradiol/drospirenone) |
| SELECT CONTRACEPTIVE PRODUCTS, ORAL CONTRACEPTIVES | YAZ (ethinyl estradiol/drospirenone) |
| SKELETAL MUSCLE RELAXANTS | OZOBAX (baclofen) |
| STIMULANTS AND RELATED AGENTS, LONG-ACTING | VYVANSE (lisdexamfetamine) |
| STIMULANTS AND RELATED AGENTS, LONG-ACTING | VYVANSE CHEWABLE (lisdexamfetamine) |